Liu L, Lv X, Zhou S, et al. - Among patients with major depressive disorder with impaired cognitive function, this investigation was carried out to determine how treatment with selective serotonin reuptake inhibitors could impact cognitive function in this population and also to examine the influencing factors. Participants were split into the cognitive remission and nonremission groups. The final analysis involved 160 patients (mean age 37.6±10.8 years, 30.6% male). The median (quartiles) baseline Global Deficit Score (GDS) was 1.4 (0.8, 1.9) and HRSD17 was 19.5 (17.0, 23.0). Post-treatment improvement in all five cognitive domains was evident, while only 41 (25.6%) patients achieved cognitive remission. The identified risk factors for cognitive nonremission included recurrent episodes and a higher baseline GDS. There may be required more aggressive interventions in order to promote cognitive remission in clinical practice, particularly for cases with severe cognitive impairment and recurrent episodes.